Argentarii’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.53M Buy
5,644
+10
+0.2% +$11.8K 1.99% 9
2026
Q2
$6.85M Sell
5,634
-33
-0.6% -$33.7K 2.06% 9
2026
Q1
$5.21M Buy
5,667
+9
+0.2% +$9.12K 1.82% 11
2025
Q4
$6.08M Buy
5,658
+842
+17% +$805K 1.98% 9
2025
Q3
$3.67M Buy
4,816
+72
+2% +$53.6K 1.47% 16
2025
Q2
$3.7M Hold
4,744
– – 1.7% 13
2025
Q1
$3.92M Buy
4,744
+54
+1% +$44.9K 1.94% 11
2024
Q4
$3.62M Buy
+4,690
New +$3.88M 1.82% 11

Other funds holding LLY

Argentarii's LLY Position: Q3 2026 in Review

Argentarii increased its Eli Lilly (LLY) stake by 0.18% in Q3 2026, buying an estimated $11.8K and bringing the position to 5,644 shares worth $6.53M. The position accounts for 1.99% of the portfolio, ranked #9.

Argentarii first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $6.85M in Q2 2026. 1,995 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Argentarii held 5,644 shares of Eli Lilly worth $6.53M as of Q3 2026.
  • Argentarii bought 10 Eli Lilly shares in Q3 2026, an estimated $11.8K.
  • Eli Lilly made up 1.99% of Argentarii's portfolio in Q3 2026, its #9 holding.
  • Argentarii first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • Argentarii's Eli Lilly position peaked at $6.85M in Q2 2026.
  • 1,995 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Argentarii's 13F filing for Q3 2026, filed 28 Oct 2026.